Diffusion Pharmaceuticals Presents Early Findings Showing Increased Survival in Lead-in Portion of Phase 3 Glioblastoma Study with TSC plus Standard of … CHARLOTTESVILLE, Va., May 13, 2016 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (OTCQX:DFFN), a clinical stage biotechnology … CHARLOTTESVILLE, Va., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company focused on the development of novel small … Diffusion Pharmaceuticals Appoints Life Sciences Veteran Dr. Robert Cobuzzi, Jr. to its Board of Directors 19 November, 2019 Diffusion Pharmaceuticals Presents Early Findings Showing Increased Survival in Lead-in Portion of Phase 3 Glioblastoma Study with TSC plus Standard of Care Company Release - 2/8/2017 8:00 AM ET.
Diffusion Pharmaceuticals Inc. DFFN, +3.24%, a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for … Diffusion Pharmaceuticals Inc. is an innovative biotechnology company developing new treatments that improve the body’s ability to bring oxygen to the areas where it … The average life expectancy post-diagnosis is less than 2 years. Company Release - 5/13/2016 11:45 AM ET. Diffusion Pharmaceuticals is a tiny micro-cap with market cap between $4.6m and $11.1m (based on a price of $0.285), developing an add-on treatment for brain cancer (glioblastoma) and stroke. Our most advanced program is in first line treatment of glioblastoma, a life-threatening cancer of the glial cells in the brain, affecting 28,000 patients worldwide. Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of … GBM is one of the most hypoxic cancers, and this hypoxia causes significant resistance to both radiation and chemotherapy.
Diffusion Pharmaceuticals’ TSC Phase 1/2 Glioblastoma Multiforme Clinical Trial Results Published in February 2017 Edition of Journal of Neurosurgery. Diffusion Pharmaceuticals Announces Publication of TSC Phase 1/2 Glioblastoma Multiforme Trial Data in the Journal of Neurosurgery Data Suggest Increase in Tumor Shrinkage and Survival with TSC .